SCI

6 June 2024

Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer

(IF: Cancer Cell, 50.3)

  • Dyikanov D, Zaitsev A, Vasileva T, Wang I, Sokolov AA, Bolshakov ES, Frank A, Turova P, Golubeva O, Gantseva A, Kamysheva A, Shpudeiko P, Krauz I, Abdou M, Chasse M, Conroy T, Merriam NR, Alesse JE, English N, Shpak B, Shchetsova A, Tikhonov E, Filatov I, Radko A, Bolshakova A, Kachalova A, Lugovykh N, Bulahov A, Kilina A, Asanbekov S, Zheleznyak I, Skoptsov P, Alekseeva E, Johnson JM, Curry JM, Linnenbach AJ, South AP, Yang E, Morozov K, Terenteva A, Nigmatullina L, Fastovetz D, Bobe A, Balabanian L, Nomie K, Yong ST, Davitt CJH, Ryabykh A, Kudryashova O, Tazearslan C, Bagaev A, Fowler N, Luginbuhl AJ, Ataullakhanov RI, Goldberg MF. Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer. Cancer Cell. 2024 May 13;42(5):759-779.e12. 

  • Correspondence: michael.goldberg@bostongene.com

The lack of comprehensive diagnostics and consensus analytical models for evaluating the status of a patient’s immune system has hindered a wider adoption of immunoprofiling for treatment monitoring and response prediction in cancer patients. To address this unmet need, we developed an immunoprofiling platform that uses multiparameter flow cytometry to characterize immune cell heterogeneity in the peripheral blood of healthy donors and patients with advanced cancers. Using unsupervised clustering, we identified five immunotypes with unique distributions of different cell types and gene expression profiles. An independent analysis of 17,800 open-source transcriptomes with the same approach corroborated these findings. Continuous immunotype-based signature scores were developed to correlate systemic immunity with patient responses to different cancer treatments, including immunotherapy, prognostically and predictively. Our approach and findings illustrate the potential utility of a simple blood test as a flexible tool for stratifying cancer patients into therapy response groups based on systemic immunoprofiling.

由于缺乏评估患者免疫系统状态的全面诊断和一致性分析模型,阻碍了免疫谱分析在癌症患者治疗监测和反应预测中的广泛应用。为了解决这一未满足的需求,我们开发了一个免疫谱分析平台,该平台使用多参数流式细胞术来表征健康捐赠者和晚期癌症患者的周围血液中的免疫细胞异质性。利用无监督聚类,我们确定了五种免疫类型,它们具有不同细胞类型和基因表达谱的独特分布。使用相同方法对17,800个开源转录组进行的独立分析证实了这些发现。我们开发了基于免疫类型的连续特征评分,以将全身免疫与患者对不同癌症治疗(包括免疫治疗)的反应相关联,使其具有预后和预测价值。我们的方法和发现说明了简单的血液测试可作为一种灵活工具的潜在效用,可根据全身免疫谱分析将癌症患者分层为治疗反应组。